RESULTS: 1% Clascoterone Cream. (3 months Jan-Mar 2026) 3/28/2026
The user reported slight improvement in hairline using 1% Clascoterone cream over three months but found it too costly to continue. They expressed interest in trying a 5% concentration if it becomes available at a reasonable price.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Using 1% Clascoterone cream on hairline?
A 30-year-old man with hairline recession is considering using 1% Clascoterone cream on his hairline while awaiting a 5% Breezula product. He has been using oral Minoxidil for four years but stopped using Finasteride due to side effects.
community Clascoterone 5% solution infographic
Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.
community Clascoterone 12 months phase 3 result out
Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.
community Clascoterone - Why are there so few posts if it’s already on the market?
Clascoterone is being discussed for hair loss, but its current acne formulation may not be suitable for scalp use due to potential skin irritation and lower dosage compared to Breezula. Users mention other treatments like finasteride, minoxidil, and pyrilutamide, with some expressing skepticism about clascoterone's effectiveness for hair loss.
community Clascoterone powder already available?
Clascoterone powder is now available, but it's expensive and not widely discussed due to past ineffective results at higher concentrations. Users are skeptical about its effectiveness and are seeking reliable sources.
Related Research
6 / 6 resultsresearch Real-World Experience of Clascoterone Cream 1% in Acne Management: Case Series and Canadian Experience
This case series involving 10 patients treated with clascoterone cream 1% for acne vulgaris found it effective and well-tolerated, regardless of severity, age, gender, or ethnicity, and noted additional benefits for related skin conditions.
research Clascoterone Cream 1% in Acne Management: Case Series and Real-World Canadian Experience
In this case series, treatment with clascoterone cream 1% was reported to be effective and well tolerated for diverse acne vulgaris patients, improving clinical outcomes whether used alone or in combination with other therapies, and addressing various other skin conditions.
research Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream
This review discusses the clinical trials of clascoterone 1% cream for acne vulgaris and reports no new results; the authors highlight its novel role as a topical antiandrogen.
research Industry update: the latest developments in the field of therapeutic delivery, July 2018
This industry update reports on various advancements in therapeutic delivery during July 2018, highlighting active mergers, collaborations, and potential developments across fields like gene therapy, immuno-oncology, and rare diseases treatment; however, no new clinical results are presented.
research Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review
This review reports that innovative topical treatments for dermatologic conditions like acne and atopic dermatitis show minimal systemic absorption, indicating improved safety and tolerability compared to traditional therapies.
research Use of topical clascoterone for the treatment of hidradenitis suppurativa
This article discusses the challenges in treating hidradenitis suppurativa, highlighting that adalimumab is currently the only FDA-approved treatment, and reports no clinical results.